MCID: MNN032
MIFTS: 53

Meningococcal Meningitis

Categories: Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Meningococcal Meningitis

MalaCards integrated aliases for Meningococcal Meningitis:

Name: Meningococcal Meningitis 12 58 15 17 71 32
Meningitis, Meningococcal 74 44
Meningitis Meningococcal 54

Characteristics:

Orphanet epidemiological data:

58
meningococcal meningitis
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/100000 (France),1-9/100000 (New Zealand),1-9/1000000 (United States);

Classifications:

Orphanet: 58  
Rare neurological diseases


Summaries for Meningococcal Meningitis

Disease Ontology : 12 A bacterial meningitis that has material basis in Neisseria meningitidis infection.

MalaCards based summary : Meningococcal Meningitis, also known as meningitis, meningococcal, is related to meningococcemia and meningitis. An important gene associated with Meningococcal Meningitis is CFP (Complement Factor Properdin), and among its related pathways/superpathways are Innate Immune System and Toll-like Receptor Signaling Pathway. The drugs Immunoglobulins and Antibodies have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and skin, and related phenotypes are fever and hypoglycorrhachia

Wikipedia : 74 Meningococcal disease describes infections caused by the bacterium Neisseria meningitidis (also termed... more...

Related Diseases for Meningococcal Meningitis

Diseases related to Meningococcal Meningitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 223)
# Related Disease Score Top Affiliating Genes
1 meningococcemia 31.2 MBL2 CFP
2 meningitis 30.7 TLR9 TLR4 TLR2 MBL2 CFP C3
3 haemophilus influenzae 30.6 TLR2 CFH
4 glomerulonephritis 30.2 MBL2 CFP CFH C3
5 complement component 5 deficiency 30.1 CFP CFHR2 C3
6 membranoproliferative glomerulonephritis 29.9 CFP CFHR2 CFH C3
7 neisseria meningitidis infection 29.9 TLR4 TLR2 MBL2 DHPS CFP C3
8 bacterial meningitis 29.8 TLR9 TLR4 TLR2 MBL2 CFP C3
9 complement deficiency 29.5 MBL2 CFP CFHR2 CFH C7 C6
10 complement component 3 deficiency 29.5 MBL2 CFP CFHR2 CFH C3
11 disease by infectious agent 29.3 TLR9 TLR4 TLR2 SIGLEC5 MBL2 CFHR2
12 fungal infectious disease 29.3 TLR4 TLR2 DENND2B
13 candidiasis 29.3 TLR4 TLR2 MBL2
14 measles 29.3 TLR9 TLR4 TLR2
15 otitis media 29.0 TLR4 TLR2 MBL2 C3
16 thrombocytopenia 28.6 TLR9 TLR4 TLR2 MBL2 CFH C3
17 streptococcus pneumonia 28.5 TLR9 TLR4 TLR2 SIGLEC5 CFHR2 C3
18 meningococcal infection 10.6
19 pericarditis 10.5
20 branchiootic syndrome 1 10.4
21 exanthem 10.4
22 exudative glomerulonephritis 10.3 CFHR2 CFH
23 purpura 10.3
24 mannose-binding lectin deficiency 10.3 MBL2 CFP
25 ataxia and polyneuropathy, adult-onset 10.3
26 pleural empyema 10.3
27 endophthalmitis 10.3
28 waterhouse-friderichsen syndrome 10.3
29 anti-basement membrane glomerulonephritis 10.3 CFP CFHR2
30 complement component 6 deficiency 10.2
31 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.2
32 purpura fulminans 10.2
33 disseminated intravascular coagulation 10.2
34 toxic shock syndrome 10.2
35 pneumococcal meningitis 10.2
36 atypical hemolytic uremic syndrome with complement gene abnormality 10.2 CFH C3
37 scabies 10.2 MBL2 CFP
38 genetic atypical hemolytic-uremic syndrome 10.2 CFH C3
39 yemenite deaf-blind hypopigmentation syndrome 10.2
40 subdural empyema 10.2
41 paraplegia 10.2
42 vasculitis 10.2
43 louse-borne relapsing fever 10.2 CFH C3
44 diffuse glomerulonephritis 10.2 CFP C3
45 tick-borne relapsing fever 10.1 CFHR2 C3
46 angioid streaks 10.1 CFHR2 CFH
47 complement component 7 deficiency 10.1
48 complement component 9 deficiency 10.1
49 sensorineural hearing loss 10.1
50 hydrocephalus 10.1

Graphical network of the top 20 diseases related to Meningococcal Meningitis:



Diseases related to Meningococcal Meningitis

Symptoms & Phenotypes for Meningococcal Meningitis

Human phenotypes related to Meningococcal Meningitis:

58 31 (show all 35)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
2 hypoglycorrhachia 58 31 hallmark (90%) Very frequent (99-80%) HP:0011972
3 increased csf protein 58 31 hallmark (90%) Very frequent (99-80%) HP:0002922
4 csf pleocytosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0012229
5 stiff neck 58 31 hallmark (90%) Very frequent (99-80%) HP:0025258
6 nuchal rigidity 58 31 hallmark (90%) Very frequent (99-80%) HP:0031179
7 photophobia 58 31 frequent (33%) Frequent (79-30%) HP:0000613
8 anorexia 58 31 frequent (33%) Frequent (79-30%) HP:0002039
9 skin rash 58 31 frequent (33%) Frequent (79-30%) HP:0000988
10 sepsis 58 31 frequent (33%) Frequent (79-30%) HP:0100806
11 petechiae 58 31 frequent (33%) Frequent (79-30%) HP:0000967
12 headache 58 31 frequent (33%) Frequent (79-30%) HP:0002315
13 elevated c-reactive protein level 58 31 frequent (33%) Frequent (79-30%) HP:0011227
14 projectile vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002587
15 hypotension 58 31 occasional (7.5%) Occasional (29-5%) HP:0002615
16 hearing impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0000365
17 increased intracranial pressure 58 31 occasional (7.5%) Occasional (29-5%) HP:0002516
18 renal insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0000083
19 irritability 58 31 occasional (7.5%) Occasional (29-5%) HP:0000737
20 paresthesia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003401
21 lethargy 58 31 occasional (7.5%) Occasional (29-5%) HP:0001254
22 drowsiness 58 31 occasional (7.5%) Occasional (29-5%) HP:0002329
23 papilledema 58 31 occasional (7.5%) Occasional (29-5%) HP:0001085
24 abnormality of the anterior fontanelle 58 31 occasional (7.5%) Occasional (29-5%) HP:0000236
25 seizure 31 occasional (7.5%) HP:0001250
26 hypothermia 58 31 very rare (1%) Very rare (<4-1%) HP:0002045
27 encephalitis 58 31 very rare (1%) Very rare (<4-1%) HP:0002383
28 cranial nerve paralysis 58 31 very rare (1%) Very rare (<4-1%) HP:0006824
29 neonatal respiratory distress 58 31 very rare (1%) Very rare (<4-1%) HP:0002643
30 stroke 58 31 very rare (1%) Very rare (<4-1%) HP:0001297
31 shock 58 31 very rare (1%) Very rare (<4-1%) HP:0031273
32 acute disseminated intravascular coagulation 58 31 very rare (1%) Very rare (<4-1%) HP:0011880
33 seizures 58 Occasional (29-5%)
34 reduced consciousness/confusion 58 Frequent (79-30%)
35 purpura 58 Occasional (29-5%)

MGI Mouse Phenotypes related to Meningococcal Meningitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.65 ATP2B3 C3 C6 C7 C9 CFH
2 renal/urinary system MP:0005367 9.17 C3 CFH DHPS MBL2 TLR2 TLR4

Drugs & Therapeutics for Meningococcal Meningitis

Drugs for Meningococcal Meningitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 20)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunoglobulins Phase 4
2 Antibodies Phase 4
3 Immunologic Factors Phase 4
4 Vaccines Phase 4
5
Aluminum hydroxide Approved, Investigational Phase 2, Phase 3 21645-51-2
6
Lactitol Approved, Investigational Phase 3 585-86-4 157355
7
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 11953898 15589840
8
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
9
Cobalamin Experimental Phase 2, Phase 3 13408-78-1 6857388
10 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
11 Cathartics Phase 3
12 Gastrointestinal Agents Phase 3
13 Laxatives Phase 3
14 Vitamin B 12 Phase 2, Phase 3
15 Vitamin B12 Phase 2, Phase 3
16 Pharmaceutical Solutions Phase 3
17
Aluminum sulfate Approved Phase 2 10043-01-3
18 Antipyretics Phase 2
19
Phenylalanine Approved, Investigational, Nutraceutical 63-91-2 6140
20 Antibiotics, Antitubercular

Interventional clinical trials:

(show top 50) (show all 95)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Single Center, Open-Label, Controlled, Randomized Study to Evaluate the Memory Response of Children Previously Vaccinated With Chiron Meningococcal C Conjugate Vaccine, Menjugate® and Describe the Kinetic of the Antibody Response and Maturation on Days 2-7 and 28 After Challenge With Pasteur Merieux Meningococcal A/C Polysaccharide Vaccine or Menjugate® Unknown status NCT00262015 Phase 4
2 Cluster-randomized Trial to Evaluate the Impact of Ciprofloxacin for Contacts of Cases of Meningococcal Meningitis as an Epidemic Response Completed NCT02724046 Phase 4 Ciprofloxacin
3 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix®) and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine (Gardasil®) in Healthy Adolescents When Administered With MenACWY Conjugate Vaccine Completed NCT01424644 Phase 4
4 Assay of the Immunogenicity of Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine in Africa Completed NCT00271479 Phase 4
5 Postmarketing Surveillance Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in the Republic of Korea Completed NCT02864927 Phase 4
6 Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately Four Years Earlier Completed NCT02633787 Phase 4
7 Immunogenicity and Safety of Two-Dose Series of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284; Menactra®) in Japanese Healthy Adult Subjects Completed NCT02591290 Phase 4
8 A Sourcing Study to Collect Human Biological (Serum) Samples From Healthy Adults Recruiting NCT03493919 Phase 4
9 Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population (ProPositive Study) Recruiting NCT03682939 Phase 4
10 A Phase IV Randomized, Observer-blind, Controlled Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine as Compared to Sanofi Pasteur Menactra® Vaccine in Healthy Subjects Aged 2-10 Years Not yet recruiting NCT04450498 Phase 4
11 Cluster-randomized Trial to Evaluate the Impact of Ciprofloxacin Prophylaxis as a Response to a Meningococcal Meningitis Epidemic Withdrawn NCT03431675 Phase 4 Ciprofloxacin
12 Immunogenicity, Reactogenicity and Safety Assessment of the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos / FIOCRUZ in Infants, Children and Adolescents Unknown status NCT02858570 Phase 2, Phase 3
13 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults Completed NCT01466387 Phase 3
14 An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers Completed NCT00422292 Phase 3
15 An Immunogenicity and Safety Evaluation of Two Doses of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) Given to Healthy Subjects at 9 and 12 Months of Age Completed NCT00384397 Phase 3
16 A Phase 2/3, Open Label, Randomised Study of the Safety, Reactogenicity and Immunogenicity of a Single Dose of Novartis Meningococcal ACWY (Menveo) or GSK Meningococcal ACWY Conjugate Vaccine in Adolescents Primed With Meningitec, Menjugate or Neisvac-C in Preschool Vaccination Completed NCT01192997 Phase 2, Phase 3
17 A Phase IIIb, Open-Label, Controlled, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine Completed NCT01148017 Phase 3
18 A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine Administered to Healthy Infants and Toddlers Completed NCT00667602 Phase 3
19 A Phase 3, Partially Blinded, Randomized, Multi-Center, Controlled Study to Evaluate Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants Completed NCT00657709 Phase 3
20 A Phase 3, Multi-center Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adults and Compare to the Safety and Immune Response of a Licensed Conjugate Meningococcal ACWY Vaccine in Subjects Aged 19-55 Years of Age and to a Licensed Polysaccharide Vaccine in Subjects Aged 56-65 Years of Age. Completed NCT00474487 Phase 3
21 A Phase 3, Single-Center, Open-label, Controlled, Randomized Study to Evaluate the Safety and Immunogenicity of Novartis Men ACWY Vaccine Administered Either Alone or Concomitantly With a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine in Healthy Adolescents Completed NCT00518180 Phase 3
22 Safety Study of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered With Other Pediatric Vaccines to Healthy Toddlers Completed NCT00483574 Phase 3
23 An Open-Label, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercially Available MenACWY Conjugate Vaccine Completed NCT00856297 Phase 3
24 A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Safety And Tolerability Of A Meningococcal Serogroup B Bivalent Recombinant Lipoprotein (rlp2086) Vaccine Given In Healthy Subjects Aged Greater Than Or Equal To 10 To Less Than 26 Years Completed NCT01352793 Phase 3
25 An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of the Concomitant Use of a Live Pentavalent Rotavirus Vaccine (RotaTeq®) and a Meningococcal Group C Conjugate (MCC) Vaccine in Healthy Infants Completed NCT00443846 Phase 3
26 A Randomized, Open-Label Trial of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants Completed NCT00161928 Phase 3
27 A Phase 3, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants Completed NCT00474526 Phase 3
28 Phase 3b, Open Label, Uncontrolled, Single-arm, Single-centre Study to Evaluate the Safety of Two Doses of Novartis Meningococcal Group B Vaccine When Administered to Healthy Adults From 18 to 50 Years of Age and to Collect Blood Donations to Develop Vaccines Against Neisseria Meningitidis Completed NCT02305446 Phase 3
29 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Other Pediatric Vaccines in Healthy Toddlers Completed NCT03205371 Phase 3
30 A Phase 3, Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 11 to 55 Years of Age in Korea Completed NCT01274897 Phase 3
31 A Phase 3b, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life. Completed NCT01214837 Phase 3
32 A Phase 2b/3, Multi-Center, Extension Study of V72P10 to Assess Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10. Completed NCT01148524 Phase 2, Phase 3
33 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults Completed NCT01453348 Phase 3
34 Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults Completed NCT02752906 Phase 3
35 A Phase 3b, Single-Center, Open-label Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-risk Adults Completed NCT01478347 Phase 3
36 A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years Completed NCT01339923 Phase 3
37 A Phase 3, Randomized, Comparative, Multicenter Observer-Blind Study Evaluating the Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years Completed NCT01423084 Phase 3
38 A Phase 3, Multi-center Study to Evaluate Lot to Lot Consistency, Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults and Compare to the Safety and Immune Response to a Licensed Conjugate Meningococcal ACWY Vaccine Completed NCT00450437 Phase 3
39 A Phase 3, Multi-Center, Observer Blind, Controlled, Randomized Study to Compare the Immunogenicity and Safety of the Concomitant Administration of a Combined Tetanus, Reduced Diphtheria, and Acellular Pertussis (Tdap) Vaccine and Chiron (Now Novartis) Meningococcal ACWY Conjugate Vaccine, With Either One Dose of Acellular Pertussis (Tdap) Vaccine, or One Dose of Chiron (Now Novartis) Meningococcal ACWY Conjugate Vaccine, in Healthy Subjects Aged 11-25 Years Completed NCT00329901 Phase 3
40 A Phase 2b, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis Meningococcal B Recombinant Vaccine Administered at 12, 18 or 24 Months of Age in Subjects Who Previously Received a Three-Dose Primary Series of the Novartis Meningococcal B Recombinant Vaccine as Infants in Study V72P12 Completed NCT00944034 Phase 2, Phase 3
41 Immunogenicity and Safety of a Single Dose of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects Completed NCT01519713 Phase 3
42 A Phase 3, Open Label, Multi-Center, Extension Study to Assess Antibody Persistence and Response to a Third or Fifth Dose of Novartis Meningococcal B Recombinant Vaccine in 4-Year-Old Children Who Previously Participated in Study V72P12E1 Completed NCT01717638 Phase 3
43 Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults Aged 10 to 55 Years Completed NCT02842853 Phase 3
44 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children 2 to 9 Years of Age Completed NCT03077438 Phase 3
45 A Phase IIIb, Open Label, Multi Center Extension Study of V72_28 to Assess Antibody Persistence, and the Safety and Tolerability of a Booster Dose After the Completion of the Vaccination Course in Study V72_28 Completed NCT01894919 Phase 3
46 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults Age 56 Years and Older Completed NCT02842866 Phase 3
47 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers 12 to 23 Months of Age. Completed NCT02955797 Phase 3
48 A Randomized, Double-Blind, Controlled, Non-inferiority Phase III Trial of a Group A Meningococcal Polysaccharide Vaccine in Healthy Infants Aged 6-15 Months Recruiting NCT04689165 Phase 3
49 A Randomized, Double-Blind, Controlled, Non-inferiority Phase III Trial of a Group A and C Meningococcal Polysaccharide Vaccine in Healthy Children Aged 2-6 Years Recruiting NCT04689191 Phase 3
50 A Phase IIIB, Randomized, Controlled, Observer-blind Study to Evaluate Safety and Immunogenicity of GSK's Meningococcal ABCWY Vaccine When Administered in Healthy Adolescents and Adults, Previously Primed With Meningococcal ACWY Vaccine Recruiting NCT04707391 Phase 3 Placebo

Search NIH Clinical Center for Meningococcal Meningitis

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Chloramphenicol sodium succinate

Cochrane evidence based reviews: meningitis, meningococcal

Genetic Tests for Meningococcal Meningitis

Anatomical Context for Meningococcal Meningitis

MalaCards organs/tissues related to Meningococcal Meningitis:

40
Brain, Spinal Cord, Skin, Neutrophil, Endothelial, Bone, Lymph Node

Publications for Meningococcal Meningitis

Articles related to Meningococcal Meningitis:

(show top 50) (show all 1515)
# Title Authors PMID Year
1
[Predisposing factors of community acquired bacterial meningitis (excluding neonates)]. 61 54
19419829 2009
2
[Immunology in the medical practice. XXVII. Mannose-binding lectin, an important link for nonspecific or hereditary immune reaction]. 61 54
10897301 2000
3
Association of familial deficiency of mannose-binding lectin and meningococcal disease. 61 54
10509505 1999
4
Meningococcal vaccines in China. 61
33566720 2021
5
Subdural and subarachnoid empyema as a complication of an acute meningococcal meningitis. 61
31630118 2021
6
Herpes simplex virus type 2 myelitis mimicking ICU-acquired weakness as a complication of meningococcal meningitis: A case report. 61
33207270 2021
7
Miller Fisher syndrome following meningococcal meningitis. 61
32725464 2020
8
Meningococcal vaccines and protein-energy undernutrition in children in the African meningitis belt. 61
33223309 2020
9
Interactions and Signal Transduction Pathways Involved during Central Nervous System Entry by Neisseria meningitidis across the Blood-Brain Barriers. 61
33233688 2020
10
Structure of a protective epitope reveals the importance of acetylation of Neisseria meningitidis serogroup A capsular polysaccharide. 61
33158970 2020
11
The important role of immunization in alcoholic and non-alcoholic chronic liver disease: A population-based study. 61
32729256 2020
12
4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp. 61
33007046 2020
13
Rapid Diagnosis of Meningococcal Meningitis in a Patient With Familial Mediterranean Fever by the FilmArray Meningitis/Encephalitis Panel: A Case Report. 61
32983350 2020
14
Primary immunization of meningococcal meningitis vaccine among children in Hangzhou, China, 2008-2017. 61
32961071 2020
15
Diversification in immunogenicity genes caused by selective pressures in invasive meningococci. 61
32776867 2020
16
Long-term impacts of MenC vaccination campaign in the Salvador, Brazil metropolitan region: A comparison of pre- and post-vaccine periods. 61
32741673 2020
17
Profile and complexity of travel medicine consultations in Chile: unicentric cross-sectional study. 61
32883733 2020
18
An Update on Meningococcal Vaccination. 61
32752565 2020
19
Meningococcal meningitis and COVID-19 co-infection. 61
32843469 2020
20
Combined therapy with ceftriaxone and doxycycline does not improve the outcome of meningococcal meningitis in mice compared to ceftriaxone monotherapy. 61
32660552 2020
21
Pediatric bacterial meningitis and meningococcal disease profile in a Brazilian General Hospital. 61
32598866 2020
22
Neisseria meningitidis Infection of Induced Pluripotent Stem-Cell Derived Brain Endothelial Cells. 61
32744533 2020
23
Recurrent meningococcal meningitis with complement 6 (C6) deficiency: A case report. 61
32481330 2020
24
Characteristics and outcome of spontaneous bacterial meningitis in patients with diabetes mellitus. 61
32312231 2020
25
An assessment of the use of Hepatitis B Virus core protein virus-like particles to display heterologous antigens from Neisseria meningitidis. 61
32178907 2020
26
Health workers' perceptions and challenges in implementing meningococcal serogroup a conjugate vaccine in the routine childhood immunization schedule in Burkina Faso. 61
32075630 2020
27
Validation of a New Rapid Detection Test for Detection of Neisseria meningitidis A/C/W/X/Y Antigens in Cerebrospinal Fluid. 61
31915288 2020
28
The Origin of the Idea That Herpes Labialis Is of Prognostic Importance in Bacterial Meningitis. 61
32222716 2020
29
Differences in the courses of meningococcal and pneumococcal cerebrospinal meningitis. 61
31956973 2020
30
Surveillance system assessment in Guinea: Training needed to strengthen data quality and analysis, 2016. 61
32584846 2020
31
Cerebrospinal meningitis: a global disease with regional variability? 61
32115677 2020
32
Unusual presentation of meningococcal meningitis in the elderly and utility of CSF PCR testing. 61
33195972 2020
33
COVID-19 and lessons learned from the pandemic wave of meningococcal meningitis (1985-1990). 61
32528206 2020
34
Genetic Variation in Neisseria meningitidis Does Not Influence Disease Severity in Meningococcal Meningitis. 61
33262994 2020
35
[Paroxysmal nocturnal hemoglobinuria treated with eculizumab in Wakayama, Japan: a retrospective analysis]. 61
32624532 2020
36
Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery. 61
31762464 2019
37
Development a multi-epitope driven subunit vaccine for immune response reinforcement against Serogroup B of Neisseria meningitidis using comprehensive immunoinformatics approaches. 61
31394292 2019
38
Cuban Meningococcal Vaccine VA-MENGOC-BC:30 Years of Use and Future Potential. 61
32335565 2019
39
Meningitis vaccines in children: what have we achieved and where next? 61
31335439 2019
40
MenAfriNet: A Network Supporting Case-Based Meningitis Surveillance and Vaccine Evaluation in the Meningitis Belt of Africa. 61
31671453 2019
41
Epidemiology of Bacterial Meningitis in the Nine Years Since Meningococcal Serogroup A Conjugate Vaccine Introduction, Niger, 2010-2018. 61
31671439 2019
42
Bacterial Meningitis Epidemiology in Five Countries in the Meningitis Belt of Sub-Saharan Africa, 2015-2017. 61
31671441 2019
43
Neisseria meningitidis Serogroup W Meningitis Epidemic in Togo, 2016. 61
31671438 2019
44
Spatiotemporal Analysis of Serogroup C Meningococcal Meningitis Spread in Niger and Nigeria and Implications for Epidemic Response. 61
31671446 2019
45
Meningococcal Meningitis Outbreaks in the African Meningitis Belt After Meningococcal Serogroup A Conjugate Vaccine Introduction, 2011-2017. 61
31671449 2019
46
A case report of multiple cerebral abscess formation complicating serogroup B Neisseria meningitidis meningitis. 61
31638913 2019
47
A case of a FilmArray® ME false negative in meningococcal meningitis. 61
31102602 2019
48
Meningococcal meningitis presenting postinfant group B meningococcal immunisation. 61
30518518 2019
49
Changes in the Molecular Epidemiology of Pediatric Bacterial Meningitis in Senegal After Pneumococcal Conjugate Vaccine Introduction. 61
31505635 2019
50
Reactive vaccination as a control strategy for pneumococcal meningitis outbreaks in the African meningitis belt: Analysis of outbreak data from Ghana. 61
29371015 2019

Variations for Meningococcal Meningitis

Expression for Meningococcal Meningitis

Search GEO for disease gene expression data for Meningococcal Meningitis.

Pathways for Meningococcal Meningitis

Pathways related to Meningococcal Meningitis according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.74 TLR9 TLR4 TLR2 SIGLEC5 MBL2 CFP
2
Show member pathways
12.85 TLR9 TLR4 TLR2 MBL2 C3
3 12.01 TLR9 TLR4 TLR2 C3
4
Show member pathways
11.9 MBL2 CFH C9 C7 C6 C3
5 11.85 TLR4 TLR2 MBL2 C3
6
Show member pathways
11.83 TLR9 TLR4 TLR2
7 11.73 TLR4 TLR2 C9
8
Show member pathways
11.7 MBL2 CFP CFH C9 C7 C6
9 11.69 MBL2 CFH C3
10
Show member pathways
11.66 TLR9 TLR4 TLR2
11
Show member pathways
11.57 TLR9 TLR4 TLR2
12 11.55 TLR9 TLR4 TLR2 C3
13
Show member pathways
11.54 MBL2 CFP C9 C7 C6 C3
14 11.49 TLR9 TLR4 TLR2
15 11.41 TLR4 TLR2 C3
16 11.33 MBL2 CFHR2 CFH C9 C7 C6
17 11.31 TLR9 TLR4 TLR2

GO Terms for Meningococcal Meningitis

Cellular components related to Meningococcal Meningitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.81 TLR9 MBL2 CFP CFHR2 CFH C9
2 blood microparticle GO:0072562 9.26 INTS11 CFH C9 C3
3 membrane attack complex GO:0005579 8.8 C9 C7 C6

Biological processes related to Meningococcal Meningitis according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.97 TLR9 TLR4 TLR2 CFP C9 C7
2 immune system process GO:0002376 9.96 TLR9 TLR4 TLR2 MBL2 CFP CFH
3 inflammatory response GO:0006954 9.95 TLR9 TLR4 TLR2 C3
4 defense response to bacterium GO:0042742 9.92 TLR9 TLR4 MBL2 CFP
5 innate immune response GO:0045087 9.85 TLR9 TLR4 TLR2 MBL2 CFP CFH
6 positive regulation of inflammatory response GO:0050729 9.82 TLR9 TLR4 TLR2
7 positive regulation of interleukin-6 production GO:0032755 9.81 TLR9 TLR4 TLR2
8 positive regulation of tumor necrosis factor production GO:0032760 9.81 TLR9 TLR4 TLR2
9 complement activation, classical pathway GO:0006958 9.8 MBL2 C9 C7 C6 C3
10 complement activation GO:0006956 9.8 MBL2 CFP CFH C7 C6 C3
11 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.78 TLR9 TLR4 TLR2
12 positive regulation of interleukin-8 production GO:0032757 9.77 TLR9 TLR4 TLR2
13 toll-like receptor signaling pathway GO:0002224 9.76 TLR9 TLR4 TLR2
14 positive regulation of interleukin-12 production GO:0032735 9.74 TLR9 TLR4 TLR2
15 positive regulation of chemokine production GO:0032722 9.73 TLR9 TLR4 TLR2
16 positive regulation of interleukin-10 production GO:0032733 9.72 TLR9 TLR4 TLR2
17 positive regulation of interferon-beta production GO:0032728 9.7 TLR9 TLR4 TLR2
18 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.69 TLR9 TLR4 TLR2
19 positive regulation of interferon-alpha production GO:0032727 9.65 TLR9 TLR4
20 cytolysis GO:0019835 9.65 C9 C7 C6
21 response to molecule of bacterial origin GO:0002237 9.63 TLR9 TLR2
22 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.63 TLR9 TLR4 TLR2
23 cellular response to lipoteichoic acid GO:0071223 9.62 TLR4 TLR2
24 regulation of cytokine secretion GO:0050707 9.61 TLR9 TLR2
25 I-kappaB phosphorylation GO:0007252 9.61 TLR9 TLR4 TLR2
26 positive regulation of interleukin-18 production GO:0032741 9.59 TLR9 TLR2
27 positive regulation of toll-like receptor signaling pathway GO:0034123 9.58 TLR9 TLR2
28 positive regulation of matrix metallopeptidase secretion GO:1904466 9.54 TLR4 TLR2
29 regulation of complement activation GO:0030449 9.5 CFP CFHR2 CFH C9 C7 C6
30 positive regulation of cellular response to macrophage colony-stimulating factor stimulus GO:1903974 9.49 TLR4 TLR2
31 complement activation, alternative pathway GO:0006957 9.02 CFP CFH C9 C7 C3

Molecular functions related to Meningococcal Meningitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 TLR9 TLR4 TLR2 SYNRG SIGLEC5 MBL2
2 NAD+ nucleotidase, cyclic ADP-ribose generating GO:0061809 9.32 TLR4 TLR2
3 NAD(P)+ nucleosidase activity GO:0050135 9.26 TLR4 TLR2
4 pattern recognition receptor activity GO:0038187 9.16 TLR9 TLR2
5 lipopolysaccharide receptor activity GO:0001875 8.62 TLR4 TLR2

Sources for Meningococcal Meningitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....